December, 16 2025 Tuesday 12:12 Hrs
Last update 11-9-2025
  • SENSEX :   84,733.65

  • Top commodity trading and broking companies in India-479.71( -0.56%) 16-Dec-2025
top-arrow-market
Sensex 84718.9 -494.46  (-0.58) 16-Dec-2025
Previous Day Close
85213.36
Today's High/Low
High Low
  •  
  •  
85059.96 84683.91

Company News Details

Shilpa Medicare Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
530549
INE790G01031
137.4709721
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SHILPAMED
57.72
6332.94
EPS(TTM)
Face Value()
Div & Yield %
5.61
1
0.15
 

Shilpa Medicare Ltd
Shilpa Medicare launches NODUCA™ therapy in India
Nov 17,2025
Shilpa Medicare announced the launch of NODUCA™ (Nor Ursodeoxycholic Acid (NorUDCA)), a first-in-class therapy for the first time in India or anywhere in the world, following the historic approval granted in August 2025 by the Central Drugs Standard Control Organisation (CDSCO), India. The drugs ushers in a new line of treatment for patients suffering from metabolic dysfunction-associated fatty liver disease (MAFLD), previously referred to as non-alcoholic fatty liver disease (NAFLD).

NorUDCA offers three major therapeutic benefits for MAFLD and associated liver disorders:

- Anti-inflammatory action: Actively reduces hepatic and ductular inflammation, limiting progression to cirrhosis and liver failure.

- Anti-fibrotic effect: Promotes reversal of liver scarring (fibrosis) and stabilizes liver architecture, as proven in Phase 3 studies, with 83.3% of patients showing fibrosis reversal and 90% achieving normal liver enzyme levels within 3 months.

- Choleretic protection: Encourages toxin clearance via enhanced bile secretion and protects cholangiocytes, minimizing risk of advanced disease.

NODUCA™ (norursodeoxycholic acid), a novel bile acid therapy designed to treat metabolic dysfunction associated fatty liver disease (MAFLD), offers a first-in-class approach to improving liver health by reducing inflammation, fibrosis, and cholestasis through unique mechanisms distinct from conventional therapies.

Top
Attention Investor:
Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.